Monte Rosa Therapeutics Announced It Will Present Preclinical Data On The Potential Of Its Highly Selective Cyclin-dependent Kinase 2 (Cdk2)-directed Molecular Glue Degrader To Treat Hr-positive/Her2-negative Breast Cancer At The 2024 San Antonio...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.